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Abstract 
Objective: The emergence of metallo-β-lactamase-producing Enterobacteriaceae is a worldwide health concern. In 
this study, the first evaluation of MBL genes, blaIMP and blaVIM, in Escherichia coli resistant to imipenem isolated from 
urine and blood specimens in Qom, Iran is described. Three hundred urine and blood specimens were analysed to 
detect the presence of E. coli. Resistance to imipenem and other antimicrobials was determined by disk diffusion and 
MIC. MBL production was screened using CDDT. PCR was also carried out to determine the presence of blaIMP and 
blaVIM genes in imipenem-resistant isolates.
Results: In total, 160 E. coli isolates were collected from March to May 2016. According to disk diffusion, high-level of 
resistance (20%) to cefotaxime was observed, whereas the lowest (1%) was detected for tetracycline. In addition, five 
isolates showed resistance to imipenem with a MIC ≥ 4 µg/mL. CDDT test confirmed that five isolates were MBL-pro-
ducing strains, but no blaIMP and blaVIM genes were detected. Results of this study show a very low level of resistance 
to imipenem in our geographical area.
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Introduction
In recent years, the emergence of antimicrobial resistance 
in bacteria, mainly Enterobacteriaceae and other Gram-
negative bacteria, has become a major concern for health 
systems worldwide [1]. The impact of resistance on cost 
and length of hospitalization and increase in morbid-
ity and mortality of patients is now obvious. Resistance 
to carbapenems is considered at high frequency among 
Gram-negative bacteria, e.g. Pseudomonas aeruginosa, 
Acinetobacter spp., and Enterobacteriaceae [2–4]. Bacte-
rial β-lactamases can be categorized into four molecular 
classes based on the amino acid sequence [5]. Metallo-
β-lactamases (MBLs) or B class β-lactamases are dis-
tinct from the serine β-lactamases (classes A, C, and D) 
due to a zinc ion(s) in their structure. Except monobac-
tams, these enzymes are able to hydrolyse all β-lactam 
antibiotics, such as penicillins, cephalosporins and 
carbapenems. Different types of MBL genes have been 
described, such as blaIMP, blaVIM, blaSPM-1, blaGIM-1, 
blaSIM-1, blaKMH-1, blaDIM-1 and blaNDM-1 genes [6, 7]. 
Among these, IMP (imipenemase) and VIM (Verona 
integron-encoded MBL) types are the most common 
MBLs that have been recently recognized in Enterobac-
teriaceae [8]. MBLs are encoded both by chromosomal 
and acquired genes, called resident and acquired MBLs, 
respectively. Acquired MBLs can spread horizontally via 
mobile genetic elements among Enterobacteriaceae and 
other Gram-negative bacteria of clinical importance. In 
addition, studies showed evidence of a broad distribution 
of MBLs across different geographical areas, and that is 
considered a serious threat [9, 10]. Thus, although dif-
ferent studies on MBL-producing Escherichia coli from 
some Iranian provinces have been performed, this is the 
first study carried out in Qom city.
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Main text
Methods
Bacterial isolation and identification
This cross-sectional study was conducted on patients 
admitted to the Ali Ebne Abitaleb Center, Qom, Iran 
and the Microbiology Department of Qom University of 
Medical Sciences. During a 3-month period (March to 
May 2016), 300 blood and urine samples were collected 
from 300 patients, mean age 40  years, with some com-
mon symptoms (e.g., fever, leukocytosis, dysuria, pyuria, 
and bladder pain), following their consent. Patients with 
a previous antimicrobial consumption were excluded 
from the study. Isolation and identification of E. coli was 
performed by a standard procedure. Briefly, blood and 
urine samples were cultured onto Eosin Methylene Blue 
agar (Merck, Germany) and MacConkey agar (Merck, 
Germany) at 37  °C for 24  h. Colonies were confirmed 
by Gram staining and biochemical testing (e.g., catalase, 
oxidase, Triple Sugar Iron Agar, Sulfide Indole Motility 
(SIM), Methyl Red (MR)/Voges-Proskauer (VP), citrate 
and urease).
Antimicrobial susceptibility testing (AST)
Antimicrobial susceptibility of isolates was determined 
by standard disk diffusion method as recommended by 
the CLSI [11]. The antimicrobial disks used were imipe-
nem (IMP, 10  µg), ceftazidime (CAZ, 30  µg), amikacin 
(AK, 30 µg), tobramycin (TOB, 10 µg), gentamicin (GM, 
10 µg), tetracycline (TE, 30 µg), ceftriaxone (CRO, 30 μg), 
norfloxacin (NOR, 10 µg) ciprofloxacin (CP, 5 µg), cefex-
ime (CFM, 5  µg) nalidixic acid (NA, 30  µg), trimetho-
prim/sulfamethoxazole (SXT, 2.5 µg), amoxicillin (AMX, 
25 μg) and cefotaxime (CTX, 30 µg) (MAST, UK). E. coli 
ATCC 25922 was used as a quality control strain.
Minimum inhibitory concentrations (MICs) of imipe-
nem were also determined using the broth microdilution 
method [11]. Eight different dilutions (256, 128, 64, 32, 
16, 8, 4 and 2  μg/mL) were prepared in Mueller–Hin-
ton Broth (Merck, Germany) followed by the transfer 
of 100  μL into 96-well microtiter plates. Twenty-four 
hours cultures of E. coli colonies were suspended in 0.9% 
saline at 0.5 McFarland and then diluted (1:20). Finally, 
10 μL of the bacterial suspension was added to the wells 
and microplates were incubated aerobically at 37  °C 
for 18–24  h. E. coli strains with a MIC ≥ 4  µg/mL were 
defined as resistant strains [11].
Phenotypic identification of MBLs
Phenotypic detection of MBLs was evaluated by the com-
bination disk diffusion test (CDDT) using EDTA/imi-
penem and imipenem disks (MAST, UK) as previously 
described by Fallah et al. [12].
DNA extraction and detection of MBL genes
DNA was extracted from resistant isolates using the 
boiling method [13]. PCR was performed by using the 
primers listed in Table 1 and in a total volume of 25 μL 
composed by 12.5  µL of PCR Master Mix (SinaClon, 
Iran), 5 µL of extracted DNA, 10 p.m. of each primer syn-
thesized by Bioneer (Korea), and 5.5 µL of DNase/RNase-
free sterile water.
PCR reaction was carried out in a thermocycler 
(Eppendorf, Hamburg, Germany) as follows: denatura-
tion at 94 °C for 3 min (1 cycle), followed by 35 cycles at 
94 °C for 1 min, 55 °C for 1 min, and 72 °C for 2 min and 
a single, final, elongation step at 72 °C for 10 min. Finally, 
amplified products were analysed by electrophoresis in a 
2% agarose gel run at 95 V for 100 min in 1X TBE con-
taining DNA Safe Stain (SinaClon, Iran) and gels were 
visualized under UV light.
Results
Out of 300 clinical specimens, 160 (53%) were found 
positive to E. coli and all were urine specimen. Sixty per-
cent of strains were isolated from female and 40% from 
male patients. Disk diffusion test showed that the high-
est resistance was against cefotaxime (31 isolates, 20%) 
and ceftazidime (27 isolates, 17%) and the lowest to tet-
racycline (1 case, 1%). No resistance to amikacin and 
tobramycin was observed among isolates. Only five iso-
lates (3%) were found resistant to imipenem (Fig.  1). In 
CDDT assay, all five imipenem-resistant strains were 
confirmed positive for MBL enzymes (Fig.  2) and they 
had a MIC ≥ 4 µg/mL. PCR did not detect any blaIMP and 
blaVIM genes in MBL-producing strains.
Discussion
Over the years, the widespread use of antimicrobials has 
forced the emergence of resistance in pathogenic bacte-
ria, and this has seriously challenged their clinical effec-
tiveness. In the past, carbapenems, mainly imipenem, 
were considered drugs of the first line in empirical treat-
ment of severe bacterial infections. However, a dramatic 
increase of resistance to these antimicrobials has being 
observed in the last years and this can reduce treatment 
Table 1 Primers used in  this study to  detect blaIMP 
and blaVIM genes
Gene Primer sequences Name Size of PCR 
products 
(bp)
Refer-
ence
blaVIM 5′-GTT TGG TCG CAT ATC GCA AC-3′ VIM-F 382 [12]
5′-AAT GCG CAG CAC CAG GAT AG-3′ VIM-R
blaIMP 5′-GAA GGC GTT TAT GTT CAT AC-3′ IMP-F 587
5′-GTA TGT TTC AAG AGT GAT GC-3′ IMP-R
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options in the near future [14]. MBLs are effective 
enzymes in hydrolysing all β-lactams, except for aztre-
onam. IMP-1 and VIM-1 have been the first enzymes to 
be discovered in Japan (1990) and in Italy (1999), respec-
tively. Afterward, many variants have been described in 
other countries. Currently, more than 20 different IMP 
and VIM types are known [9, 15, 16]. MBL-producing 
bacteria, e.g. E. coli, Pseudomonas aeruginosa, Klebsiella 
spp., Acinetobacter baumannii, have been reported from 
different parts of Iran [3, 17–19] and this has become a 
major threat to public health [20]. E. coli is considered 
an opportunist pathogen and cause of urinary infections, 
bacteraemia, neonatal meningitis, but the emergence of 
MBL-producing strains is rapidly growing and threating 
successful therapy [21]. Therefore, detection of resistance 
in E. coli from different areas is crucial to avoid its spread 
among bacteria.
In this study, all E. coli positive cultures were obtained 
from urine samples. This finding is in agreement with 
Ntirenganya et  al. [22] who found 55.2% of positive 
cases related to urine specimens. In our E. coli isolates, 
the highest level of resistance was detected against cefo-
taxime (20%), ceftazidime (17%), ciprofloxacin (14%) 
and trimethoprim/sulfamethoxazole (14%). The lowest 
level of resistance was identified against imipenem (3%), 
gentamycin and tetracycline (1%), while no resistance to 
tobramycin and amikacin (0%) was detected. In other 
Iranian regions, different resistance levels have been 
reported. Mansouri [23] reported very high resistance 
rates of E. coli to trimethoprim/sulfamethoxazole (93.4%) 
and amoxicillin (91.4%) in Kerman city, Iran. Unlike our 
study, the Authors did not report resistance to imipenem. 
Pouladfar et al. [24] reported two imipenem-resistant uri-
nary E. coli (1.9%) in Shiraz, Iran. The full susceptibility of 
our isolates to tobramycin and amikacin is similar to that 
obtained in other countries, such as Spain [25]. However, 
resistance to these antimicrobials has been observed in 
other studies. For example, Soleimani et al. [26] detected 
resistance to aminoglycosides among uropathogenic E. 
coli isolated from Tehran, Iran. In addition, they showed 
that 24.6 and 3.62% of isolates were resistant to tobramy-
cin and amikacin, respectively. Another report from 
Punjab, Pakistan, showed 59% and 91% of resistance to 
tobramycin and amikacin, respectively [26, 27].
MIC results were comparable with those obtained at 
disk diffusion, which showed 3% of isolates resistant to 
imipenem. A very low level of resistance was observed by 
Moayednia et  al. [28] in Isfahan city, Iran. The Authors 
detected 0.3% (2/720) of hospital E. coli isolates posi-
tive for MBL, while no MBL-producing isolates were 
detected in non-hospital E. coli. In contrast to our study, 
Zeighami et al. [29] did not detect any MBL-positive E. 
coli in Zanjan City, Iran. Besides Iran, the presence of 
MBL-producing E. coli has been reported from other 
parts of the world. Bora et  al. [30] in Nepal indicated a 
high prevalence of MBLs with 18.98 and 21.08% for  E. 
coli  and K. pneumonia, respectively. Other studies car-
ried out in Korea and India also detected an increasing 
frequency of MBL positive strains within the Enterobac-
teriaceae family [31, 32].
In this study, no blaIMP and blaVIM genes were found, 
but we cannot exclude that other MBL genes might have 
been involved in resistance. It is cleared that the resist-
ance to carbapenems may be attributed to outer mem-
brane protein deletion and significantly a decrease in cell 
permeability can be seen [33]. In study of the Ranjan and 
co-worker [34], blaKPC gene could not be detected among 
isolated E. coli, while they were positive for blaNDM and 
blaOXA-48. Additionally, although phenotypic tests are 
easy and have an excellent sensitivity, the use of EDTA 
can give false positive results due to the instability of 
the bacterial membrane [35, 36]. In agreement with our 
study, Lee et al. [37] found only one out of three imipe-
nem-resistant E. coli isolates as MBL producer and har-
bouring MBL genes in southern Taiwan. In another study 
carried out by Peirano et  al. [38], the majority of VIM- 
and IMP-producing Enterobacteriaceae were K. pneu-
moniae and only one E. coli strain was found positive. A 
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Fig. 2 MBL phenotypic test. Disk A; imipenem and disk B; imipenem/
EDTA combination. The inhibition zone of B was interpreted as 
positive
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high prevalence of MBL-producing E. coli was detected 
in the study of Nahid et al. [39] in Pakistan. The Authors 
showed that, out of 145 E. coli, 50 (34.48%) were MBL 
producers and VIM and IMP genes were present in eight 
and two strains, respectively.
In conclusion, our study is the first description of MBL-
producing E. coli in Qom, Iran. Overall, strains showed 
a low resistance level to imipenem and none was found 
positive for  blaIMP and blaVIM genes. Therefore, pheno-
typing assays are recommended for detecting resistance 
in E. coli, as well as a guideline on the prudent use of anti-
microbials should be developed for preventing the emer-
gence and spread of resistance.
Limitations
Due to financial constraints, we could not focus on other 
genes only.
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